AUTL logo

AUTL
Autolus Therapeutics Ltd - ADR

3,461
Mkt Cap
$338M
Volume
2M
52W High
$3.45
52W Low
$1.11
PE Ratio
-1.50
AUTL Fundamentals
Price
$1.23
Prev Close
$1.27
Open
$1.33
50D MA
$1.50
Beta
1.21
Avg. Volume
2.75M
EPS (Annual)
-$0.8652
P/B
1.70
Rev/Employee
$15,648.00
Loading...
Loading...
News
all
press releases
Autolus Therapeutics (NASDAQ:AUTL) Downgraded to Strong Sell Rating by Wall Street Zen
Wall Street Zen lowered shares of Autolus Therapeutics from a "hold" rating to a "strong sell" rating in a report on Saturday...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
FY2029 EPS Estimate for Autolus Therapeutics Cut by Analyst
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Analysts at William Blair dropped their FY2029 earnings per share (EPS) estimates for shares of Autolus Therapeutics in a research...
MarketBeat·5d ago
News Placeholder
Autolus Therapeutics (NASDAQ:AUTL) Announces Quarterly Earnings Results
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.24...
MarketBeat·7d ago
News Placeholder
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.
Zacks·10d ago
News Placeholder
Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens
CHMP has recommended that the European Commission approve the therapy for treating adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia.
Stocktwits·6mo ago
News Placeholder
Autolus Therapeutics (AUTL) Gets a Buy from Truist Financial
In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Autolus Therapeutics (AUTL Research Report). The...
TipRanks Financial Blog·1y ago
News Placeholder
China Universal Asset Management Co. Ltd. Invests $105,000 in Autolus Therapeutics plc (NASDAQ:AUTL)
China Universal Asset Management Co. Ltd. bought a new stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the 4th quarter, according to its most recent 13F filing with the...
Zolmax·2y ago
News Placeholder
Autolus Therapeutics (NASDAQ:AUTL) Shares Down 7.5%
Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) dropped 7.5% during trading on Monday . The stock traded as low as $5.90 and last traded at $5.90. Approximately 1,050,329 shares were traded...
Ticker Report·2y ago
News Placeholder
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-AL
Submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in r/r B-ALLThe US marketing application is under review with a Prescription Drug User Fee Act (PDUFA) target action...
Globe Newswire·2y ago
News Placeholder
Autolus Therapeutics (AUTL, $5.68) price exceeded its 50-day Moving Average on April 01, 2024
This price move could indicate a change in the trend, and may be a sell signal for investors...
Tickeron - Stocks·2y ago

Latest AUTL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.